Study of ARO-APOC3 in Adults With Mixed Dyslipidemia
- Registration Number
- NCT04998201
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Brief Summary
Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluted for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recommended by the Investigator in accordance with local standard of care. After week 48, participants will be eligible and invited to consent and continue in an open-label extension study. All placebo participants who opt to continue will switch to active drug (ARO-APOC3) during the extension study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 353
Based on medical history, evidence of TG ≥ 150 mg/dL but ≤ 499 mg/dL on more than one occasion
- Fasting levels at Screening of non-HDL-C ≥ 100 mg/dL OR LDL-C ≥ 70 mg/dL after at least 4 weeks of stable diet and stable optimal statin therapy
- Mean fasting TG ≥ 150 mg/dL and ≤ 499 mg/dL during Screening collected at two separate and consecutive visits and at least 7 days apart and not more than 14 days apart
- Willing to follow diet counseling as per Investigator judgment based on local standard of care
- Participants of childbearing potential (males & females) must use highly-effective contraception during the study and for at least 24 weeks following the last dose of study medication. Males must not donate sperm and females must ot donate eggs during the study and for at least 24 weeks following the last dose of study medication.
- Women of childbearing potential must have a negative pregnancy test at Screening and cannot be breastfeeding
- Women of childbearing potential on hormonal contraceptives must be stable on the medication for ≥ 2 menstrual cycles prior to Day 1
- Willing to provide written informed consent and to comply with study requirements
- Current use or use within 365 days from Day 1 of any hepatocyte targeted siRNA or antisense oligonucleotide molecule
- Active pancreatitis within 12 weeks prior to Day 1
- Any planned bariatric surgery or similar procedures to induce weight loss from consent through end of study
- Acute coronary syndrome event within 24 weeks of Day 1
- Major surgery within 12 weeks of Day 1
- Planned coronary intervention (e.g., stent placement or heart bypass) during the study
- New York Heart Association Class II, III or IV heart failure or last known ejection fraction of <30%
- Uncontrolled hypertension
- Known history of human immunodeficiency virus (HIV) infection, seropositive for Hepatitis B (HBV), seropositive for Hepatitis C (HCV)
- Uncontrolled hypothyroidism or hyperthyroidism
- Hemorrhagic stroke within 24 weeks of Day 1
- History of bleeding diathesis or coagulopathy
- Current diagnosis of nephrotic syndrome
- Systemic use of corticosteroids or anabolic steroids within 4 weeks prior to Day 1 or planned use during the study
- Malignancy within the last 2 years prior to date of consent requiring systemic treatment (some exceptions apply)
Note: additional inclusion/exclusion criteria may apply per protocol
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ARO-APOC3 10 mg, Day 1 and Week 12 ARO-APOC3 2 doses of ARO-APOC3 by subcutaneous (sc) injection ARO-APOC3 25 mg, Day 1 and Week 12 ARO-APOC3 2 doses of ARO-APOC3 by subcutaneous (sc) injection ARO-APOC3 50 mg, Day 1 and Week 12 ARO-APOC3 2 doses of ARO-APOC3 by subcutaneous (sc) injection ARO-APOC3 50 mg, Day 1 and Week 24 ARO-APOC3 2 doses of ARO-APOC3 by subcutaneous (sc) injection Placebo, Day 1 and Week 12 or Week 24 Placebo calculated volume to match active treatment by sc injection
- Primary Outcome Measures
Name Time Method Percent Change from Baseline in Fasting Triglycerides (TG) at Week 24 Baseline, Week 24
- Secondary Outcome Measures
Name Time Method Number of Participants with Treatment- Emergent AEs and/or SAEs Through Week 48 up to Week 48 Change from Baseline in Plasma Concentrations of ARO-APOC3 Over Time up to Week 24 Percent Change from Baseline in APOC-III Over Time Baseline, up to Week 48 Percent Change from Baseline in Apolipoprotein (APO) C-III at Week 24 Baseline, Week 24 PK of ARO-APOC3: Time to Maximum Plasma Concentration (Tmax) up to Week 24 Percent Change from Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 Baseline, Week 24 Percent Change from Baseline in Fasting TG Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 36, Week 48 Percent Change form Baseline in Non-HDL-C Over Time Baseline, up to Week 48 Percent Change from Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 24 Baseline, Week 24 Percent Change from Baseline in HDL-C Over Time Baseline, up to Week 48 Percent Change from Baseline in Fasting Total Apolipoprotein B (ApoB) at Week 24 Baseline, Week 24 Percent Change from Baseline in ApoB Over Time Baseline, up to Week 48 Percent Change from Baseline in Fasting Total Low Density Lipoprotein Cholesterol (LDL-C) Using Ultracentrifugation at Week 24 Baseline, Week 24 Percent Change from Baseline in Fasting Total LDL-C Using Ultracentrifugation Over Time Baseline, up to Week 48 Number of Participants with Treatment-Emergent Adverse Events (AEs) and/or Serious Adverse Events (SAEs) at Week 24 Week 24 Pharmacokinetics (PK) of ARO-APOC3: Maximum Observed Plasma Concentration (Cmax) up to Week 24 PK of ARO-APOC3: Area Under the Plasma Concentration Versus Time Curve From Zero to Time of Last Measurable Concentration (AUClast) up to Week 24
Trial Locations
- Locations (30)
Alta Pharmaceutical Research Center
🇺🇸Dunwoody, Georgia, United States
Preventive Cardiology Inc.
🇺🇸Boca Raton, Florida, United States
A & R Research Group
🇺🇸Pembroke Pines, Florida, United States
Invesclinic U.S.; LLC
🇺🇸Fort Lauderdale, Florida, United States
Monash Health
🇦🇺Clayton, Victoria, Australia
Baylor College of Medicine
🇺🇸Houston, Texas, United States
Prestige Clinical Research
🇺🇸Franklin, Ohio, United States
Westside Medical Associates of Los Angeles
🇺🇸Beverly Hills, California, United States
Valley Clinical Trials, Inc
🇺🇸Northridge, California, United States
Ocean Blue Medical Research Center, Inc.
🇺🇸Miami Springs, Florida, United States
Mid Hudson Medical Research, PLLC
🇺🇸New Windsor, New York, United States
University of Sunshine Coast Morayfield
🇦🇺Morayfield, Queensland, Australia
BFHC Research
🇺🇸San Antonio, Texas, United States
Royal Adelaide Hospital
🇦🇺Adelaide, South Australia, Australia
LMC Diabetes & Endocrinology
🇨🇦Concord, Ontario, Canada
Institut de Recherches Cliniques de Montreal
🇨🇦Montréal, Quebec, Canada
DRC Gyogyszervizsgalo
🇭🇺Balatonfüred, Hungary
University of Debrecen-Clinical Center
🇭🇺Debrecen, Hungary
Borbanya Praxis Kft.
🇭🇺Nyiregyhaza, Hungary
Southern Clinical Trials Christchurch
🇳🇿Christchurch, New Zealand
Centrum Medyczne Medyk
🇵🇱Rzeszów, Poland
Clinical Research of South Nevada
🇺🇸Las Vegas, Nevada, United States
Primed Clinical Research
🇺🇸Dayton, Ohio, United States
Tribe Clinical Research
🇺🇸Greenville, South Carolina, United States
East Texas Cardiology PA
🇺🇸Houston, Texas, United States
Genesis Care Joondalup
🇦🇺Joondalup, Western Australia, Australia
Middlemore Hospital
🇳🇿Auckland, New Zealand
Praktyka Lekarska Ewa Krzyzagorska
🇵🇱Poznań, Poland
All-MED Centrum Medyczne
🇵🇱Łódź, Poland
Instytut Centrum Zdrowia Matki Polki
🇵🇱Łódź, Poland